PNC Financial Services Group Inc. Boosts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

PNC Financial Services Group Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,636 shares of the biotechnology company’s stock after purchasing an additional 164 shares during the period. PNC Financial Services Group Inc.’s holdings in United Therapeutics were worth $580,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Healthcare of Ontario Pension Plan Trust Fund boosted its position in United Therapeutics by 540.5% in the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,700 shares of the biotechnology company’s stock worth $5,211,000 after purchasing an additional 20,000 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of United Therapeutics by 5.8% during the 4th quarter. Fisher Asset Management LLC now owns 3,828 shares of the biotechnology company’s stock valued at $842,000 after buying an additional 209 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at $1,353,000. Trail Ridge Investment Advisors LLC lifted its position in shares of United Therapeutics by 7.2% during the 4th quarter. Trail Ridge Investment Advisors LLC now owns 1,635 shares of the biotechnology company’s stock valued at $360,000 after buying an additional 110 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its position in shares of United Therapeutics by 16.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 161,539 shares of the biotechnology company’s stock valued at $35,521,000 after buying an additional 23,211 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on UTHR. Oppenheimer upped their price target on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Wells Fargo & Company upped their price target on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Finally, JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $312.22.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $232.37, for a total value of $1,394,220.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $8,530,302.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,166.50. The disclosure for this sale can be found here. Insiders have sold 122,744 shares of company stock worth $31,286,630 in the last ninety days. 12.50% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $318.95 on Thursday. The firm has a market capitalization of $14.15 billion, a P/E ratio of 15.08, a P/E/G ratio of 4.77 and a beta of 0.49. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The stock’s 50-day simple moving average is $271.56 and its two-hundred day simple moving average is $243.07. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $321.80.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company earned $4.86 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.